Efficacy of Hetrombopag Combined with Cyclosporine A in the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia
The optimal treatment for transfusion-dependent non-severe aplastic anemia (TD-NSAA) remains uncertain. While UK guidelines recommend intensified immunosuppressive therapy (IST) as a first-line treatment for TD-NSAA, the associated costs and risks are relatively high. A recent study conducted by Professor Guangsheng He's team at Jiangsu Provincial People's Hospital, presented at the 65th American Society of Hematology (ASH) Annual Meeting, explored the effectiveness of Hetrombopag combined with Cyclosporine A (CsA) in treating TD-NSAA. The study provides crucial insights for clinical consideration. Here is a summary.